The present invention relates to a pharmaceutical composition for the treatment of vitiligo comprising the combination of a peptide which is an inhibitor of the melanoma inhibitory activity (MIA) protein and snail secretion. The invention also relates to a kit comprising this composition and a dietary supplement comprising an antioxidant. The invention also relates to the use of the composition or to the use of the kit comprising such composition for the prevention and/or treatment of vitiligo.

Provided herein are formulations containing copper ions and methods of treating underlying infections and conditions caused by coronavirus, particularly COVID-19, and influenzas, particularly influenza A and/or influenza B using such formulations. Methods of treating the underlying viruses and their resultant conditions using topical copper ion treatments are provided. A topical treatment in its basic form comprises a biocompatible copper ion solution or suspension obtained by leaching of the copper ions from copper metal. The copper ion solution or suspension may be combined with various carriers to form the copper ion treatment including creams or solutions. Methods of making the copper ion solution or suspension from solid copper metal in a biocompatible solution are also provided.

Disclosed herein are topical compositions of 5-α reductase inhibitors, such as dutasteride or finasteride, or a pharmaceutically acceptable salt, ester, or derivative thereof and the use of the compositions for the treatment of hair loss secondary to endocrine therapy in patients with breast cancer (Endocrine Therapy-Induced Alopecia or ETIA), androgenetic alopecia (AGA), alopecia areata, and hirsutism. The topical composition is advantageous over the existing oral compositions of 5-α reductase inhibitors because the topical composition is safer and more effective. The topical formulation may allow for a slow release of the active ingredient dutasteride, better penetration at the therapeutically effective amount of dutasteride with an improved safety profile because it does not need to travel through the bloodstream to be efficacious, thereby minimizing the risk of systemic side effects.

A topical application of nitric oxide may be provided by two separate containers, each containing an active component media to produce nitric oxide when combined. For example, a nitrite component media may be contained in one dispenser and an acidified component media may be contained in another dispenser. Each dispenser may dispense the respective component media as a foam. The resultant foams are combined to initiate the production of nitric oxide and the mixture of foams is applied topically to treat various skin disorders or wounds.

A method for the production of a rhamnolipid. The method includes culturing in a fermentation medium an organism capable of producing a rhamnolipid to form a fermentation broth comprising at least one rhamnolipid and having a pH>5; extracting at least one lipophilic impurity from said fermentation broth; acidulating said fermentation broth to form an aqueous medium of pH<5 comprising the at least one rhamnolipid; extracting the at least one rhamnolipid from said acidulated fermentation broth; and separating the at least one rhamnolipid to obtain a purified rhamnolipid.

The present invention relates to an ethanol foam sclerosing agent for vascular anomalies and a preparation method thereof. The ethanol foam sclerosing agent includes absolute ethanol, water, Tween 80 and a stabilizer. The ethanol foam sclerosing agent further includes hyaluronic acid. The mass composition of the ethanol foam sclerosing agent includes 32-42% of absolute ethanol, 0.5-2% of Tween 80, 0-25% (excluding 0) of egg yolk lecithin, 0-2% (excluding 0) of hyaluronic acid, and the balance of water. The stabilizer is hyaluronic acid or glycerin. Foam is prepared by the Tessari method. While the original therapeutic effect of ethanol is not changed, the side effect of the ethanol is significantly reduced.

Nanoparticulate, ion-paired complexes of melittin (MLN) and one or more non-steroidal anti-inflammatory drugs, and particularly MLN ion-paired with diclofenac, provide for enhanced wound healing in humans and other animals. Compositions having the nanonparticulates distributed therein or thereon are applied topically to the wound, and the ion-paired complexes have been shown to demonstrate superior wound healing and closure.

Disclosed are topical compositions and methods of treatment of skin disorders selected from Molluscum contagiosum, verrucae and warts by topical administration to a subject in need thereof of a composition comprising between about 0.5%-1.0% w/w high-purity cantharidin. Also disclosed are processes for preparation of high-purity cantharidin.

The invention relates in particular to an injectable sclerosant drug foam comprising: (i) a matrix; (ii) at least one fluid; (iii) at least one sclerosant drug; (iv) a medical gas or medical gas mixture acceptable for intravenous use, (v) wherein said matrix has physical properties, which are comparable to denatured blood, wherein the denatured blood is obtainable from a fresh human venous whole blood sample of 1 ml volume, which is heated in a cylindrical polyethylene container with 3 mm inner diameter and 3.4 mm outer diameter for about 0.5 min. to about 10 min. at a temperature of about between 70° C. and 100° C. and/or (vii) said level of denaturation is defined by the change of red-colored hemoglobin to brown as an indicator, wherein Fe.sup.2+ is reduced to Fe.sup.3+ in the hemoglobin complex to a degree of at least 80%, preferably 90% and even more preferably 95%.

The present disclosure provides pharmaceutical compositions for treating fungal and bacterial infections. The pharmaceutical compositions of the disclosure comprise a cationic surfactant, a chelating agent, and at least one solvent. The pharmaceutical compositions of the disclosure can be used to treat drug-sensitive or multi drug-resistant bacterial or fungal infections.